Regeneron (REGN) Chosen as Backup Bidder in 23andMe Asset Sale | REGN Stock News

23andMe has agreed to sell its Personal Genome Service, Research Services, and Lemonaid Health business to TTAM Research Institute for $305 million, superseding Regeneron's initial $256 million offer, pending court approval scheduled for June 17, 2025. Separately, Regeneron reported Q1 2025 revenue of $3 billion, driven by a 20% increase in Dupixent global sales, though EYLEA US sales declined 39%; analysts forecast a one-year average price target of $735.55 for Regeneron, indicating a potential 39% upside.

Analysis

Regeneron Pharmaceuticals (REGN) was an active participant in the recent 23andMe asset sale, being designated the backup bidder with a $256 million offer before TTAM Research Institute secured the deal for $305 million, indicating REGN's strategic interest in acquisitions. This context surrounds Regeneron's Q1 2025 financial results, which depicted a robust underlying business with notable product-specific challenges. The company reported total revenues of $3 billion, significantly driven by Dupixent's continued strength, with global net sales surging 20% year-over-year to $3.7 billion, and the promising growth of EYLEA HD, whose US net sales increased 54% year-over-year to $307 million. Conversely, flagship product EYLEA experienced a substantial 39% year-over-year decline in US net sales to $736 million, impacted by heightened competition and reduced wholesaler inventory. Despite this pressure, Regeneron demonstrated financial resilience, ending Q1 with $17.6 billion in cash and marketable securities, generating $816 million in free cash flow, and actively returning capital to shareholders through $1.1 billion in share repurchases and a $0.88 quarterly dividend. The company also raised its full-year 2025 gross margin guidance to 86-87%. Analyst sentiment is generally positive, reflected in an average price target of $735.55 (implying 38.98% upside from $529.24) and a consensus "Outperform" rating, though concerns persist regarding regulatory hurdles, such as the FDA's complete response letter for the EYLEA HD prefilled syringe, and ongoing competitive pressures on EYLEA.

Key Decisions for Investors

• Investors should weigh Regeneron's strong growth from Dupixent and EYLEA HD, alongside its solid financial position and capital return program, against the considerable challenges facing the original EYLEA product and recent regulatory delays.
• Closely monitor the EYLEA franchise dynamics, including the impact of competition on the legacy formulation, the sales trajectory of EYLEA HD, and the timeline for resolving the EYLEA HD prefilled syringe Complete Response Letter.
• Recognize the long-term growth potential embedded in Regeneron's extensive pipeline of approximately 45 clinical candidates, while also factoring in the execution risk highlighted by previous regulatory setbacks and the need for successful clinical and commercial translation.
• Given the analyst consensus "Outperform" rating and significant target price upside, consider the current valuation relative to growth prospects but remain vigilant regarding competitive intensity in key markets and the company's ability to navigate the regulatory environment effectively.